About us
We are SYNformulas – the company behind the brand Kijimea. Since our founding in 2011, we have pursued a clear vision: to harness the potential of the microbiota (bacteria) in our gut to promote longer and healthier lives for everyone.
A major milestone on this journey was achieved in 2013 with the discovery and clinical research of the unique bacterial strain Bifidobacterium bifidum MIMBb75 (Kijimea Irritable Bowel). Since then, we have significantly improved the lives of millions of IBS patients worldwide. Today, B. bifidum MIMBb75 is one of the most extensively studied bacterial strains globally. Its effectiveness and unique mode of action have been demonstrated in numerous clinical studies and published in prestigious journals, including The Lancet.
We collaborate with leading research institutions such as Charité Berlin to explore the connections between the microbiota (bacteria in our gut) and allergies, skin conditions, and mental health disorders. In short, we investigate how gut bacteria can influence a longer and healthier life.
Today, we are among the fastest-growing healthcare companies worldwide. We reach our customers through various channels: direct communication with doctors and pharmacists, as well as print, TV, and digital marketing. Our goal is clearly defined: by 2028, we aim to make Kijimea the world’s largest DTC probiotic brand, improving the lives of over 50 million people annually.
A major milestone on this journey was achieved in 2013 with the discovery and clinical research of the unique bacterial strain Bifidobacterium bifidum MIMBb75 (Kijimea Irritable Bowel). Since then, we have significantly improved the lives of millions of IBS patients worldwide. Today, B. bifidum MIMBb75 is one of the most extensively studied bacterial strains globally. Its effectiveness and unique mode of action have been demonstrated in numerous clinical studies and published in prestigious journals, including The Lancet.
We collaborate with leading research institutions such as Charité Berlin to explore the connections between the microbiota (bacteria in our gut) and allergies, skin conditions, and mental health disorders. In short, we investigate how gut bacteria can influence a longer and healthier life.
Today, we are among the fastest-growing healthcare companies worldwide. We reach our customers through various channels: direct communication with doctors and pharmacists, as well as print, TV, and digital marketing. Our goal is clearly defined: by 2028, we aim to make Kijimea the world’s largest DTC probiotic brand, improving the lives of over 50 million people annually.